CA
NZ
UK
AU
IND
US
● Healthcare Triangle cut its maximum equity-line draw per notice from $2.5 million to $250,000 in a September 22, 2026 amendment.
● OrbiMed Advisors and two affiliated funds disclosed a new 11.0% stake of 6,885,170 shares in Electra Therapeutics on September 25, 2026.
● Cencora, Inc. (NYSE:COR) appointed former Ryder System CEO Robert Sanchez to its board effective October 1, 2026.
● Co-Diagnostics failed to reach quorum at its annual meeting on both September 3 and September 24, 2026.
● Alterity Therapeutics scheduled itsAnnual General Meetingfor 11:00 a.m. AEDT on Friday, November 20, 2026.
● Aquestive Therapeutics furnished an updated corporate investor presentation to the SEC as Exhibit 99.1 on September 23, 2026.
● Acadia's Phase 2 RADIANT study narrowly missed its primary endpoint on the SAPS-H+D scale at six weeks.
● A Tennessee federal court granted preliminary approval on September 1, 2026 to settle four consolidated derivative lawsuits.
Momentum stocks tend to follow a familiar pattern. Strong runs attract new buyers, pullbacks test conviction, and the stocks that hold their gains through those pullbacks often have the strongest fundamental support. Today's session offers a small data point on that test.
The five stocks also sit at different points in their development. Fennec already generates product revenue, while Capricor and DiaMedica remain focused on clinical milestones. Enanta and Arcturus fall somewhere in between, with established platforms and pipelines that have seen mixed sentiment over time.
Please wait processing your request...